| Literature DB >> 29879952 |
Abstract
BACKGROUND: Metabolic syndrome (MetS) increases the incidence of cardiovascular disease and diabetes mellitus. It is essential to study the natural progression of MetS in the interest of prevention. Information on the dynamic changes in MetS in developing countries is limited. This study aimed to simulate the progression of each component of MetS and explore the potential role of these components in early prevention and intervention.Entities:
Keywords: Intervention; Metabolic syndrome; Obesity; Prediction
Mesh:
Year: 2018 PMID: 29879952 PMCID: PMC5992701 DOI: 10.1186/s12889-018-5599-y
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Fig. 1A 7-state Markov model to describe the progression of MetS components
Prevalence of components of MetS at baseline and various lengths of follow-up [n(%)]
| Follow-up years | ||||||
|---|---|---|---|---|---|---|
| Baseline | 1 | 2 | 3 | 4 | 5 | |
| N | 5881 | 5881 | 3518 | 2065 | 1346 | 825 |
| Male | 2476 (42.10) | 2476 (42.10) | 1356 (38.54) | 637 (30.85) | 388 (28.83) | 279 (33.82) |
| Hypertension | 740 (12.58) | 901 (15.32) | 576 (16.37) | 361 (17.48) | 296 (21.99) | 221 (26.79) |
| Obesity | 1795 (30.52) | 1942 (33.02) | 1135 (32.26) | 653 (31.62) | 431 (32.02) | 293 (35.52) |
| Hyperglycemia | 529 (9.00) | 593 (10.08) | 349 (9.92) | 206 (9.98) | 170 (12.63) | 138 (16.73) |
| Dyslipidemia | 1278 (21.73) | 1316 (22.38) | 782 (22.23) | 431 (20.87) | 276 (20.51) | 189 (22.91) |
| MetS | 249 (4.23) | 431 (7.57) | 256 (7.28) | 158 (7.65) | 136 (10.10) | 110 (13.33) |
The interval between any two consecutive follow-up years was 1 year
Annual transition probabilities (%) in Markov chain models for men in the 20- to 40-year-old age group
| Original state | Follow-up state | ||||||
|---|---|---|---|---|---|---|---|
| No components | Isolated hypertension | Isolated obesity | Isolated hyperglycemia | Isolated dyslipidemia | 2 components | MetS | |
| No components | 76.40 | 2.86 | 6.72 | 1.29 | 7.30 | 4.72 | 0.71 |
| Isolated hypertension | 16.95 | 49.16 | 8.48 | 1.69 | 1.69 | 16.95 | 5.08 |
| Isolated obesity | 9.25 | 0.25 | 55.25 | 0.5 | 1.00 | 28.75 | 5.00 |
| Isolated hyperglycemia | 22.41 | 6.90 | 3.45 | 43.10 | 6.90 | 6.90 | 10.34 |
| Isolated dyslipidemia | 21.28 | 2.58 | 5.16 | 1.29 | 41.94 | 20.65 | 7.10 |
| 2 components | 5.98 | 2.00 | 21.56 | 0.80 | 4.39 | 50.90 | 14.37 |
| MetS | 1.81 | 4.55 | 10.00 | 0 | 1.82 | 29.09 | 52.73 |
Annual transition probabilities (%) in Markov chain models for men in the 40–60-year-old age group
| Original state | Follow-up state | ||||||
|---|---|---|---|---|---|---|---|
| No components | Isolated hypertension | Isolated obesity | Isolated hyperglycemia | Isolated dyslipidemia | 2 components | MetS | |
| No components | 67.63 | 6.81 | 5.79 | 2.04 | 11.24 | 5.46 | 1.03 |
| Isolated hypertension | 13.11 | 48.99 | 4.84 | 2.42 | 2.42 | 21.77 | 6.45 |
| Isolated obesity | 6.94 | 0.83 | 55.57 | 0.83 | 0.83 | 27.78 | 7.22 |
| Isolated hyperglycemia | 12.16 | 1.35 | 1.35 | 52.71 | 1.35 | 18.92 | 12.16 |
| Isolated dyslipidemia | 25.37 | 3.41 | 3.42 | 1.46 | 43.41 | 15.61 | 7.32 |
| 2 components | 2.81 | 3.07 | 13.04 | 2.05 | 4.22 | 51.79 | 23.02 |
| MetS | 2.06 | 2.57 | 2.32 | 0.52 | 0 | 23.2 | 69.33 |
Annual transition probabilities (%) in Markov chain models for women in the 20- to 40-year-old age group
| Original state | Follow-up state | ||||||
|---|---|---|---|---|---|---|---|
| No components | Isolated hypertension | Isolated obesity | Isolated hyperglycemia | Isolated dyslipidemia | 2 components | MetS | |
| No components | 87.04 | 1.70 | 3.85 | 0.81 | 3.70 | 2.15 | 0.75 |
| Isolated hypertension | 24.26 | 52.97 | 7.92 | 0 | 3.96 | 8.91 | 1.98 |
| Isolated obesity | 25.78 | 1.30 | 54.95 | 0.26 | 2.08 | 12.24 | 3.39 |
| Isolated hyperglycemia | 23.28 | 1.72 | 0 | 57.76 | 3.45 | 12.07 | 1.72 |
| Isolated dyslipidemia | 55.11 | 4.89 | 4.89 | 1.33 | 26.67 | 6.67 | 0.44 |
| 2 components | 24.68 | 5.11 | 20.85 | 2.55 | 3.83 | 34.47 | 8.51 |
| MetS | 14.29 | 4.76 | 4.76 | 0 | 4.76 | 20.63 | 50.80 |
Annual transition probabilities (%) in Markov chain models for women in the 40- to 60-year-old age group
| Original state | Follow-up state | ||||||
|---|---|---|---|---|---|---|---|
| No components | Isolated hypertension | Isolated obesity | Isolated hyperglycemia | Isolated dyslipidemia | 2 components | MetS | |
| No components | 83.78 | 3.39 | 3.85 | 1.64 | 4.85 | 1.98 | 0.51 |
| Isolated hypertension | 13.69 | 61.43 | 1.06 | 2.12 | 1.59 | 17.46 | 2.65 |
| Isolated obesity | 13.50 | 0 | 62.26 | 0 | 1.93 | 18.73 | 3.58 |
| Isolated hyperglycemia | 20.93 | 3.49 | 1.16 | 51.16 | 2.33 | 17.44 | 3.49 |
| Isolated dyslipidemia | 40.96 | 1.60 | 3.72 | 2.13 | 37.23 | 13.30 | 1.06 |
| 2 components | 8.65 | 11.90 | 14.05 | 3.78 | 4.86 | 45.41 | 11.35 |
| MetS | 2.07 | 2.07 | 4.14 | 1.38 | 0 | 17.93 | 72.41 |
Fig. 2The predicted development of MetS starting with different components in 40– to 60-year-old men
Fig. 3The predicted development of MetS starting with different components in 40– to 60-year-old women
Relative reduction in the prevalence of MetS after 10 years with intervention relative to no intervention (%)
| 30 years old | 50 years old | |||
|---|---|---|---|---|
| Intervention items | Men | Women | Men | Women |
| Hypertension intervention | 4.02 | 3.83 | 11.18 | 6.48 |
| Obesity intervention | 19.23 | 12.14 | 14.78 | 11.53 |
| Hyperglycemia intervention | 1.45 | 1.60 | 4.72 | 3.03 |
| Dyslipidemia intervention | 8.29 | 2.24 | 5.59 | 6.29 |
| Combined intervention | 32.22 | 18.85 | 34.78 | 27.9 |
Each component intervention was a hypothetical intervention such that half of individuals with an isolated component at check-up would change from the isolated abnormal state to the healthy state every year